Robust Oligonucleotide Molecular Weight Confirmation by LC-MS
Webinar Date/Time: Tue, Oct 8, 2024 11:00 AM EDT
This webcast will cover molecular weight confirmation of oligonucleotides by LC/MS, focusing on the use of fit-for-purpose deconvolution software.
Register Free: https://www.chromatographyonline.com/lcgc_w/weight-confirmation
Event Overview:
Molecular weight confirmation is a critical analytical workflow for the development of therapeutic oligonucleotides. This webinar demonstrates oligo molecular confirmation and simple characterization by LC/MS. The combination of user-friendly software, robust hardware, and unique column chemistry enables routine molecular weight confirmation for oligos of varying lengths and modifications.
Key Learning Objectives:
- Understand molecular weight confirmation for oligonucleotides by LC/MS using fir-for-purpose deconvolution software.
- Learn how to optimize your IP-RP LC/MS analytical methods to improve resolution of your target product from closely related impurities.
- Discover how the Agilent LC/MS SQ portfolio will help you develop, characterize, purify, and verify your oligonucleotides.
Who Should Attend:
- Oligonucleotide Analytical Method Development Scientists
- Oligonucleotide Purification Method Development Scientists
- Oligonucleotide Process Development Scientists
- Oligonucleotide QC Scientists
- Oligonucleotide CDMO Labs
- Oligonucleotide Developability and Development Scientists
Speakers:
Brian Rivera
Product Manager
Agilent Technologies
Brian Rivera is Software Product Manager at Agilent Technologies and has 20 years of experience in HPLC analysis of large molecules. His previous industry experience includes positions at Chiron Corporation (now Novartis), ProZyme, and Avid Bioservices. Additionally, he was Product Manager at Phenomenex, focusing on HPLC column development for monoclonal antibodies and oligonucleotides. He has a bachelor’s degree from the University of California, Davis.
Connor Flannery
Product Manager
Agilent Technologies
Connor Flannery is Global Product Manager for HPLC Biocolumns at Agilent Technologies. Prior to his work in product management, he worked as an R&D product development chemist. His work focused on the development and characterization of novel stationary phases for targeted LC applications, as well as high pressure column-packing technologies.
Russell Burge
Product Manager
Agilent Technologies
Russell Burge earned a Ph.D. in Biochemistry and Molecular Biology from Scripps Research (La Jolla, CA). He has extensive experience as a scientist in the R&D of biomolecules and biopharmaceuticals, and as an application scientist for laboratory automation systems and advanced sensor systems. Russell has managed several life sciences and industrial products, most recently of which are the LC/MS SQ and LC/MS TOF portfolios at Agilent.
Register Free: https://www.chromatographyonline.com/lcgc_w/weight-confirmation
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
